



AHCL/ SE/ 42 /2019-20

November 7 2019

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol : AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**November 07, 2019**) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter and half year ended September 30, 2019. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared First Interim Dividend of Re. 0.55 per share for the financial year 2019-20 on the Equity Shares of the Company.

The Board Meeting commenced at 11.00 A.M. and concluded at 11:20 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited




(M Srinivasan)

Company Secretary & Compliance Officer

Encl:

1. Un-audited Standalone Financials Results for the quarter and half year ended September 30 2019
2. Limited Review Report

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel : +91-44 - 2499 4465
+91-44 - 2466 9000
Fax : +91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No. : 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter and six months ended 30 September 2019

Particulars	(Rs. in Lakhs)					
	Quarter ended			Period ended		Year ended
	30 September 2019 (Unaudited)	30 June 2019 (Unaudited)	30 September 2018 (Unaudited)	30 September 2019 (Unaudited)	30 September 2018 (Unaudited)	31 March 2019 (Audited)
Continuing operations						
Income from operations						
I Revenue from operations	7,480.77	4,459.59	6,204.90	11,940.36	9,781.74	25,322.73
II Other income	186.42	155.47	154.18	341.89	286.19	713.09
III Total income (I + II)	7,667.19	4,615.06	6,359.08	12,282.25	10,067.93	26,035.82
IV Expenses						
(a) Cost of materials consumed	2,427.56	1,684.04	2,206.28	4,111.60	3,949.65	9,052.32
(b) Purchases of stock-in-trade	1,103.91	829.62	659.87	1,933.53	1,145.09	3,164.07
(c) Changes in inventories of finished goods, work in progress and stock in trade	(136.13)	(72.07)	64.99	(208.20)	(365.17)	(329.54)
(d) Employee benefits expense	1,059.94	910.82	756.56	1,970.76	1,560.29	3,336.35
(e) Advertisement and selling expenditure	1,123.12	558.27	996.98	1,681.39	1,609.63	4,109.49
(f) Finance cost	5.03	5.19	3.57	10.22	5.36	8.22
(g) Depreciation and amortisation expense	126.66	84.95	80.54	211.61	152.39	315.97
(h) Other expenses	744.83	704.80	644.63	1,449.63	1,269.48	2,862.21
Total expenses (IV)	6,454.92	4,705.62	5,413.42	11,160.54	9,326.72	22,519.09
V Profit before tax (III - IV)	1,212.27	(90.56)	945.66	1,121.71	741.21	3,516.73
VI Tax (benefit) / expenses	371.93	(20.08)	279.95	351.85	215.59	1,016.96
VII Profit after tax from continuing operations (V - VI)	840.34	(70.48)	665.71	769.86	525.62	2,499.77
Discontinued operations						
Loss before tax from discontinued operations	-	-	(16.44)	-	(29.97)	(48.34)
Tax benefit	-	-	-	-	-	-
VIII Profit / (loss) after tax from discontinued operations	-	-	(16.44)	-	(29.97)	(48.34)
IX Profit for the period (VII + VIII)	840.34	(70.48)	649.27	769.86	495.65	2,451.43
X Other comprehensive income						
Re-measurement losses / gain on defined benefit plans, net of taxes	(31.48)	(2.43)	0.31	(33.91)	9.63	(56.55)
Total other comprehensive income for the period	(31.48)	(2.43)	0.31	(33.91)	9.63	(56.55)
XI Total comprehensive income for the period (IX + X)	808.86	(72.91)	649.58	735.95	505.28	2,394.88
Paid-up equity share capital (Face value Re. 1/- each)	292.31	292.31	292.31	292.31	292.31	292.31
Earnings per equity share for continuing operations						
Basic and diluted earnings per share	2.87	(0.24)	2.28	2.63	1.80	8.55
(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
Earnings per equity share for discontinued operations						
Basic and diluted earnings per share	-	-	(0.06)	-	(0.10)	(0.17)
(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
Earnings per equity share for total operations						
Basic and diluted earnings per share	2.87	(0.24)	2.22	2.63	1.70	8.39
(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
<i>See accompanying notes to financial results</i>						



SSP



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

- The above financial results for the quarter and six months ended 30 September 2019 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 07 November 2019. The above results have been subjected to limited review by the statutory auditor of the Company. The auditors have issued an unmodified review report.
- The financial results has been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard ('Ind AS'), 34 - "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015.
- The shareholders of the Company at its Annual General Meeting held on 25 September 2019, has approved final dividend of Rs. 1.05 per equity share of Re. 1 each for the financial year ended 31 March 2019.
- The Company has elected to exercise the option permitted under section 115BAA of the Income tax Act, 1961, as introduced by the Taxation laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the half year ended September 30, 2019 and re-measured its deferred tax assets basis the rate prescribed in the said section. The impact of above mentioned change has been recognised in the statement of profit and loss for the half year ended September 30, 2019.
- Segment reporting in the financial results:** Based on the 'management approach' as defined in Ind AS 108 "Operating Segments", the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

Particulars	Quarter ended			Period ended		Year ended
	30 September 2019 (Unaudited)	30 June 2019 (Unaudited)	30 September 2018 (Unaudited)	30 September 2019 (Unaudited)	30 September 2018 (Unaudited)	31 March 2019 (Audited)
1 Segment revenue						
a OTC Products	7,158.78	3,549.72	5,870.31	10,708.50	8,683.00	23,073.35
b Beverages	244.82	854.02	296.45	1,098.84	1,024.86	2,075.98
c Others	77.17	55.85	38.14	133.02	73.88	173.40
Total	7,480.77	4,459.59	6,204.90	11,940.36	9,781.74	25,322.73
2 Segment results						
a OTC Products	1,206.66	(143.53)	1,029.70	1,063.13	1,035.97	3,645.74
b Beverages	(90.57)	8.58	(110.09)	(81.99)	(405.52)	(367.80)
c Others	(36.89)	(33.82)	(46.30)	(70.71)	(79.42)	(153.94)
Total	1,079.20	(168.77)	873.31	910.43	551.03	3,124.00
Less :						
i) Finance cost	5.03	5.19	3.57	10.22	5.36	8.22
ii) Other unallocable expenditure net of unallocable income	(138.10)	(83.40)	(75.92)	(221.50)	(195.54)	(400.95)
Total profit before tax	1,212.27	(90.56)	945.66	1,121.71	741.21	3,516.73
3 Segment assets						
a OTC Products	6,692.00	6,198.14	6,329.09	6,692.00	6,329.09	6,664.80
b Beverages	999.56	1,047.55	1,642.14	999.56	1,642.14	1,071.10
c Others	63.06	81.95	25.73	63.06	25.73	88.93
d Unallocated assets	12,151.44	10,915.52	8,599.25	12,151.44	8,599.25	10,936.51
Total	19,906.06	18,243.16	16,596.21	19,906.06	16,596.21	18,761.34
4 Segment liabilities						
a OTC Products	3,777.63	2,671.54	2,462.16	3,777.63	2,462.16	3,021.25
b Beverages	421.23	644.84	720.98	421.23	720.98	644.66
c Others	50.00	50.00	100.36	50.00	100.36	50.00
d Unallocated liabilities	717.63	376.06	241.05	717.63	241.05	471.80
Total	4,966.49	3,742.44	3,524.55	4,966.49	3,524.55	4,187.71
Total capital employed in the Company	14,939.57	14,500.72	13,071.66	14,939.57	13,071.66	14,573.63

6. Effective 1 April 2019, the Company adopted Ind AS 116 "Leases" and applied the standard to lease contracts existing on 1 April 2019 using modified retrospective approach. Accordingly, the comparatives for the year ended 31 March 2019 has not been retrospectively adjusted.

7. Pursuant to the amendment in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in relation to submission of statement of cash flows for the half-year period with effect from 01 April 2019, the statement of cash flows for the half year ended 30 September 2019 has been presented in the table below. Considering that this is the first year of applicability of the aforesaid amendment, the comparative information has been provided for the previous year ended 31 March 2019.

8. During the earlier periods, the Company had decided to discontinue the operations of its Chemical division. Accordingly, the results for the comparative periods in this Statement have been revised to exclude the operations of the Chemical division. The results of the discontinued operations are presented below:

Particulars	Quarter ended			Period ended		Year ended
	30 September 2019 (Unaudited)	30 June 2019 (Unaudited)	30 September 2018 (Unaudited)	30 September 2019 (Unaudited)	30 September 2018 (Unaudited)	31 March 2019 (Audited)
I Total revenue	-	-	1.86	-	18.77	22.87
II Total expenses	-	-	18.30	-	48.74	71.21
III Loss before tax (I - II)	-	-	(16.44)	-	(29.97)	(48.34)
IV Tax benefit	-	-	-	-	-	-
V Loss from discontinued operations (III + IV)	-	-	(16.44)	-	(29.97)	(48.34)

For Amrutanjan Health Care Limited



S Sambhu Prasad
Chairman & Managing Director

Date: 7 November 2019
Place: Chennai



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of assets and liabilities

(Rs. in Lakhs)

S. No.	Particulars	As at	As at
		30 September 2019 Unaudited	31 March 2019 Audited
A	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	2,444.84	2,527.59
	(b) Intangible assets	60.96	42.31
	(c) Right-of-use assets	167.34	-
	(d) Capital work in progress	60.30	-
	(e) Financial assets		
	Loans	47.27	56.15
	Investments	1,611.66	1,581.24
	Other financial assets	1,241.32	28.12
	(f) Tax assets	215.85	27.44
	(g) Deferred tax assets (net)	426.69	424.15
	(h) Other non-current assets	94.14	112.64
	Total non-current assets	6,370.37	4,799.64
2	Current assets		
	(a) Inventories	2,148.07	1,457.68
	(b) Financial assets		
	Investments	-	170.52
	Trade receivables	2,410.28	3,293.35
	Cash and cash equivalents	1,449.72	1,458.55
	Other bank balances	5,951.71	6,672.27
	Other financial assets	932.34	320.18
	(c) Other current assets	643.59	589.15
	Total current assets	13,535.71	13,961.70
	Total assets (1+2)	19,906.08	18,761.34
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	292.31	292.31
	(b) Other equity	14,647.26	14,281.32
	Total equity	14,939.57	14,573.63
	Liabilities		
2	Non-current liabilities		
	(a) Financial liabilities		
	Lease liabilities	118.62	-
	Other financial liabilities	23.60	27.60
	(b) Provisions	599.82	548.54
	Total non-current liabilities	742.04	576.14
3	Current liabilities		
	(a) Financial liabilities		
	Lease liabilities	54.69	-
	Trade payables	3,224.53	2,987.39
	Other financial liabilities	466.14	183.53
	(b) Provisions	188.09	230.63
	(c) Other current liabilities	291.02	210.02
	Total current liabilities	4,224.47	3,611.57
	Total equity and liabilities (1+2+3)	19,906.08	18,761.34



Handwritten signature



AMRUTANJAN HEALTH CARE LIMITED

CIN No : L24231TN1936PLC000017

Registered Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

Statement of cash flows

(Rs. in Lakhs)

Particulars	Six month ended	Year ended
	30 September 2019	31 March 2019
	(Unaudited)	(Audited)
Cash flow from operating activities		
Profit / (loss) before income tax from:		
- Continuing operations	1,121.71	3,516.73
- Discontinued operation	-	(48.34)
Adjustments for:		
Depreciation and amortisation	211.61	325.59
Property, plant and equipment written off	-	25.50
Loss on sale of property, plant and equipment	-	3.07
Loss allowance on trade receivables	62.00	46.00
Change in fair value of investments	15.86	(59.47)
Profit on sale of investments	(12.29)	-
Interest income on deposits with banks and financial institutions	(271.02)	(475.43)
Interest income on debt instruments	(37.32)	(65.12)
Excess provision written back, net	-	(67.88)
Advances written off	-	5.62
Finance costs	10.22	8.23
Unrealised loss (gain) on foreign exchange differences	(1.55)	1.15
	1,099.22	3,215.65
Working capital adjustments:		
Decrease / (increase) in trade receivables	823.31	(544.31)
(Increase) / decrease in non-current and current assets	(54.44)	209.74
Decrease in loans and other financial assets	4.69	373.13
Increase in inventories	(690.39)	(421.91)
Increase in financial liabilities	(47.30)	19.60
Increase / (decrease) in provisions	43.40	(47.28)
Increase in trade payables	237.12	343.34
Increase / (decrease) in current liabilities	17.91	(13.10)
	334.30	(80.79)
Cash generated from operating activities	1,433.52	3,134.86
Less: Income tax paid (net)	(611.36)	(1,018.03)
Net cash generated from operating activities (a)	822.16	2,116.83
Cash flow from investing activities		
Purchase or construction of property, plant and equipment, intangible assets	(159.18)	(203.91)
Proceeds from sale of property, plant and equipment	-	7.00
Investments made in deposits - other bank balances and financial assets	(772.95)	(449.63)
Interest income on deposits with banks and financial institutions	240.10	382.19
Interest income on debt instruments	60.11	97.18
(Increase) / redemption of investments	136.53	(933.99)
Net cash used in investing activities (b)	(495.39)	(1,101.16)
Cash flow from financing activities		
Dividend paid	(306.92)	(570.00)
Dividend distribution tax paid (DDT)	-	(117.16)
Payment of lease liabilities	(27.88)	-
Interest paid	(0.11)	(8.23)
Net cash used in financing activities (c)	(334.91)	(695.39)
Net increase in cash and cash equivalents (a) + (b) + (c)	(8.14)	320.28
Cash and cash equivalents at the beginning of the year	1,458.55	1,138.34
Effect of exchange rate fluctuations on cash held	(0.69)	(0.07)
Cash and cash equivalents at the end of the year	1,449.72	1,458.55
Notes to cash flow statement		
Components of cash and cash equivalents		
Cash on hand	3.39	4.43
Bank balances	175.16	357.58
Cheques on hand	1,271.17	1,096.54
	1,449.72	1,458.55



BSR



B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floor,
No 1, Harrington Road, Chetpet,
Chennai - 600 031, India.

Telephone : +91 44 4608 3100
Fax : +91 44 4608 3199

Limited Review Report

To
Board of Directors of **Amrutanjan Health Care Limited**

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** for the quarter ended and year to date results for the period from 01 April 2019 to 30 September 2019 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022



K Raghuram

Partner

Membership No: 211171

UDIN: 19211171AAAAEH9466

Place: Chennai

Date: 07 November 2019